A monoclonal antibody directed to Tn antigen

Area of Science:

• Immunology
• Glycobiology
• Cancer Research

Background:

• Monoclonal antibodies are crucial tools in cancer research.
• The Tn antigen is a tumor-associated carbohydrate antigen implicated in cancer progression.
• Characterizing novel antibodies targeting tumor antigens is essential for developing diagnostic and therapeutic strategies.

Purpose of the Study:

• To establish and characterize a novel murine monoclonal antibody, MLS 128, with potential anti-tumor activity.
• To investigate the binding specificity of MLS 128 to cancer-associated carbohydrate antigens.
• To elucidate the molecular basis of MLS 128 binding to its target antigen.

Main Methods:

• Production of monoclonal antibody MLS 128 by immunizing mice with human colonic cancer cells (LS 180).
• Binding assays using mucin glycopeptides from LS 180 cells and ovine submaxillary mucin (OSM).
• Enzymatic treatments (N-acetylgalactosaminidase and pronase) to determine the epitope recognized by MLS 128.

Main Results:

• MLS 128 was successfully established as a murine monoclonal antibody.
• The antibody demonstrated significant binding to mucin glycopeptides from LS 180 cells and their asialo forms.
• Binding was also observed with ovine submaxillary mucin (OSM) and its asialo form, indicating recognition of a core glycan structure.
• Enzymatic studies revealed that non-sialylated GalNAc residues attached to a specific peptide region are critical for MLS 128 binding.

Conclusions:

• The monoclonal antibody MLS 128 recognizes a specific non-sialylated GalNAc epitope present on mucins.
• This epitope is associated with human colonic cancer cells and may represent a target for cancer therapy.
• Further investigation of MLS 128 could lead to advancements in cancer diagnostics and treatment strategies.